Point-of-birth newborn screening for MCAD/VLCAD and galactosemia to eliminate deadly delays for time critical conditions (PA-15-269) We aim to revolutionize the traditional newborn screening paradigm by developing a point-of-care digital microfluidic platform for biochemical screening of fatty acid oxidation disorders (FAOs) and galactosemia. These disorders are inborn errors of metabolism that have profound neurological and hypoglycemic effects if not detected early. Although these disorders are included in traditional newborn screening with a multi-day turnaround, infants still die due to the deadly delays inherent to the system of transporting dried blood spots to a central laboratory. Confirmation of a diagnosis of common FAOs by enzymatic or molecular analysis can take months, leaving families in a stressful position of uncertainty. Point-of-care testing by enzyme activity is critical to address these issues. As of yet there is not a single point-of-care newborn screening technology available for biochemical screening or diagnostic confirmation. Baebies' digital microfluidic platform is a recognized innovative, affordable, automated microdroplet-based liquid handling system that can be configured to address this challenge. The digital microfluidic technology enables miniaturization of assays and significantly reduces reagent and sample volumes while providing timely data to guide clinical intervention. Baebies is guided by a vision that every newborn deserves a healthy start. Baebies' current product is for a laboratory setting and has been in use for over 2 years in the state of Missouri for the first ever newborn screening pilot study of multiple lysosomal storage disorders in the United States. The proposed point-of-birth (POB) newborn screening platform utilizes the same underlying digital microfluidic technology and aims for a time-to-result of 15 minutes so that prompt treatment through a controlled feeding schedule can be initiated. The project objective is to demonstrate technical feasibility of using digital microfluidics to detect medium-chain acyl-CoA dehydrogenase (MCAD) deficiency, very-long-chain acyl-CoA dehydrogenase (VLCAD) deficiency and galactosemia in whole blood samples for improved newborn screening at the point-of-birth. The Phase I specific aims include biochemistry development of the assays on whole blood samples, integration and analytical validation of the multiplexed panel, and preliminary method comparison using blood samples from newborns at the University of Pittsburgh. In Phase II, we will complete hardware development of the point-of- birth platform, complete development of a self-contained cartridge, and perform a pilot study for method comparison. The point-of-birth platform will have the ability to expand to other time-critical conditions in the future.
Point-of-birth newborn screening for MCAD/VLCAD and galactosemia to eliminate deadly delays for time critical conditions (PA-15-269) Baebies is guided by a vision that every newborn deserves a healthy start, irrespective of the socio-economic status and geographic location. Point-of-birth testing has the potential to overcome slow turnaround times for time-critical conditions, including MCAD, VLCAD and galactosemia. MCAD, VLCAD and galactosemia are inborn errors of metabolism that have profound neurological and hypoglycemic effects, if not detected early. The current newborn screening (NBS) paradigm relies on bloodspot screening with a multi-day time-to-result, where the delay can be deadly in disorders where the timing and type of nourishment intake can cause significant harm. The proposed point-of-birth (POB) newborn screening platform aims for a time-to-result of 15 minutes so that prompt treatment with a corrective diet can be initiated.
